Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Numab has raised €74M across 2 funding rounds from 4 investors, most recently a Series C round in Jan 2025. Based in Wadenswil, Switzerland; founded 2011; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€74M
€73,744,406
Funding rounds
2
Investors
4
distinct backers
Active since
2020-09
latest 2025-01
Funding by year
EUR raised per yearNumab — funding by year — interactive chart.
Data table
| Numab — funding by year | |
|---|---|
| 2020 | €20M |
| 2025 | €53M |
Signals
High confidenceRaise-next likelihood62
base rate 50% for Series C
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-09 | Series C | €53M | Cormorant Asset Management,Forbion,HBM Healthcare Investments,Novo Holdings | View deal → |
| 2020-09-03 | Series B | €20M | — | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData